Human resistin activates NLRP3 inflammasome in macrophages, Johns Hopkins PLOS One study finds
Johns Hopkins PLOS One study identifies resistin as an upstream activator of the NLRP3 inflammasome in macrophages, supported by patient tissue correlations and antibody blockade experiments. Findings position resistin as a potential therapeutic target for chronic inflammatory conditions. Evidence remains preliminary, derived from mechanistic and observational data requiring clinical validation.
Limitations include reliance on ex-vivo and tissue-association data without longitudinal patient outcomes or randomized intervention. Next steps require animal models of chronic inflammation followed by early-phase human safety trials targeting resistin to test whether pathway suppression alters disease course.
Johns Hopkins team: Anti-resistin antibody RGTX-23 enters first-in-human safety trial with measurable IL-1β reduction in at least 50% of participants by month 12
Sources (3)
- [1]Primary Source(https://doi.org/10.1371/journal.pone.0337682)
- [2]Supporting Source(https://www.nature.com/articles/s41577-022-00703-6)
- [3]Supporting Source(https://www.nejm.org/doi/full/10.1056/NEJMra1203528)